论文部分内容阅读
目的：进一步观察国产安吖啶的疗效及不良反应。方法：用国产安吖啶联合化疗方案治疗急性白血病初、复治病例２９１例。结果和结论：总完全缓解（ＣＲ）率４７．１％，急性淋巴细胞白血病（ＡＬＬ）为４３．３％，急性非淋巴细胞白血病（ＡＮＬＬ）为４９．０％。一线治疗无效和复发病例的ＣＲ率在ＡＬＬ和ＡＮＬＬ为２８．９％和３４．４％。国产安吖啶联合方案的不良反应与其它化疗方案相似。安吖啶的药代参数Ｃ１２ｈ／Ｃ６ｈ、Ｋ２１与疗效相关。
Objective: To further observe the efficacy and adverse reactions of domestically produced acridine. METHODS: A total of 291 patients with acute leukemia were treated with domestic anthracycline combined with chemotherapy. RESULTS AND CONCLUSION: The total complete remission (CR) rate was 47.1%, acute lymphoblastic leukemia (ALL) was 43.3%, and acute nonlymphocytic leukemia (ANLL) was 49.0%. The CR rate of first-line treatment ineffective and relapsed cases was 28.9% and 34.4% in ALL and ANLL. The adverse effects of the domestically produced analdinidine combination regimen were similar to those of other chemotherapy regimens. Ampicillin pharmacokinetic parameters C12h/C6h, K21 and efficacy.